Our R&D portfolio primarily reflects our scientific, technical and clinical competencies in vector-borne infectious diseases and in both bacterial and viral vaccines.

Vaccine Candidates

We want to make a difference in people’s lives by applying our innovative and pioneering science to address potential vaccine preventable diseases. Our pipeline includes vaccines for infectious diseases with major unmet needs in clinical development, where no vaccines are currently available.

Phase 1
Phase 2
Phase 3
Market Registration
Phase 1
Phase 2
Phase 3
Market Registration

Lyme Disease – VLA15

Lyme disease is the most common vector-borne illness in the Northern Hemisphere. Valneva's candidate is the only vaccine in clinical development worldwide. Valneva´s vaccine candidate VLA15, under Fast Track Designation by the FDA, is a multivalent vaccine that targets the outer surface protein A (OspA) of Borrelia.

View More
Phase 1
Phase 2
Phase 3
Market Registration

Chikungunya – VLA1553

Chikungunya is a mosquito-borne viral infection spreading in the Americas and Europe caused by the chikungunya virus (CHIKV), a Togaviridae virus transmitted by Aedes mosquitoes. Valneva’s vaccine candidate VLA1553, under Fast Track Designation by the FDA, is a monovalent, single dose, live-attenuated vaccine candidate against chikungunya.

View More
Phase 1
Phase 2
Phase 3
Market Registration

Zika – VLA1601

A mosquito-borne disease associated with birth defects. Since 1952, Zika outbreaks have been reported in tropical Africa, Southeast Asia, the Pacific Islands, and, in 2015, in the Americas. Valneva’s vaccine candidate, VLA1601, is a highly purified inactivated vaccine candidate against the Zika virus, developed using the same manufacturing platform as Valneva’s Japanese encephalitis vaccine.

View More
Phase 1
Phase 2
Phase 3
Market Registration

Clostridium difficile – VLA84

Clostridium difficile is a bacterium that causes diarrhea and sometimes can lead to serious intestinal conditions or complications. Valneva’s prophylactic vaccine candidate against C. difficile infection, VLA84, successfully completed Phase 2 development and is Phase 3 ready.

View More